Aurinia Pharmaceuticals AUPH Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $77.71M+0.8% | $77.11M+5.0% | $73.47M+4.9% | $70.01M+12.1% | $62.47M+4.3% | ||
| $6.51M-26.1% | $8.8M+7.6% | $8.18M+14.9% | $7.12M-17.0% | $8.57M+54.4% | ||
| $71.2M+4.2% | $68.32M+4.6% | $65.29M+3.8% | $62.89M+16.7% | $53.89M-0.8% | ||
| 91.6%+3.0pp | 88.6%-0.3pp | 88.9%-1.0pp | 89.8%+3.6pp | 86.3%-4.5pp | ||
| $7.47M-31.4% | $10.9M+29.2% | $8.44M+13.5% | $7.43M+29.4% | $5.74M-29.2% | ||
| $22.03M-24.7% | $29.26M+11.7% | $26.18M+0.6% | $26.02M+27.9% | $20.34M-45.1% | ||
| $4.82M-1.0% | $4.86M0.0% | $4.87M0.0% | $4.86M+0.2% | $4.86M-0.1% | ||
| $0— | $0— | $0-100% | $114K-92.6% | $1.53M-90.0% | ||
| -$279K— | —— | -$929K+90.0% | -$9.25M-109% | -$4.43M-198% | ||
| $36.28M-17.3% | $43.88M+0.3% | $43.72M-12.4% | $49.93M+22.9% | $40.62M-34.0% | ||
| $41.42M+24.6% | $33.24M+11.7% | $29.75M+48.1% | $20.08M-8.1% | $21.85M+1,409% | ||
| 53.3%+10.2pp | 43.1%+2.6pp | 40.5%+11.8pp | 28.7%-6.3pp | 35%+37.8pp | ||
| $1.01M-3.3% | $1.05M-4.7% | $1.1M-1.6% | $1.12M+4.7% | $1.07M-6.9% | ||
| $3.52M+0.5% | $3.5M+5.5% | $3.32M+3.9% | $3.19M-10.6% | $3.57M-10.5% | ||
| $43.93M+23.1% | $35.69M+11.7% | $31.96M+44.3% | $22.16M-9.0% | $24.35M+1,976% | ||
| $9.57M+105% | -$175.1M-42,704% | $411K-36.1% | $643K-36.0% | $1.01M— | ||
| $34.36M-83.7% | $210.79M+568% | $31.55M+46.7% | $21.51M-7.8% | $23.34M+1,534% | ||
| 44.2%-229pp | 273.4%+230pp | 42.9%+12.2pp | 30.7%-6.6pp | 37.4%+35.0pp | ||
| $0.25-83.7% | $1.53+565% | $0.23+43.8% | $0.160.0% | $0.16+1,500% | ||
| $0.26-83.8% | $1.60+567% | $0.24+50.0% | $0.16-5.9% | $0.17+1,600% | ||
| 137.6M-0.8% | 138.7M+2.0% | 136M-1.1% | 137.5M-4.0% | 143.2M-2.0% | ||
| 132.4M-1.5% | 134.4M+1.9% | 131.8M-2.3% | 134.9M-2.9% | 138.9M-2.9% | ||
| $34.07M-83.8% | $210.94M+565% | $31.71M+47.9% | $21.43M-7.5% | $23.17M+1,885% | ||
| -$279K— | —— | -$929K+90.0% | -$9.25M-109% | -$4.43M-198% | ||
| $77.71M+0.8% | $77.11M+5.0% | $73.47M+4.9% | $70.01M+12.1% | $62.47M+4.3% | ||
| $41.42M+24.6% | $33.24M+11.7% | $29.75M+48.1% | $20.08M-8.1% | $21.85M+1,409% | ||
| $46.24M+21.4% | $38.1M+10.1% | $34.61M+38.7% | $24.95M-6.6% | $26.7M+736% | ||
| $46.24M+21.4% | $38.1M+10.1% | $34.61M+38.7% | $24.95M-6.6% | $26.7M+736% | ||
| 59.5%+10.1pp | 49.4%+2.3pp | 47.1%+11.5pp | 35.6%-7.1pp | 42.7%+37.4pp | ||
| $41.42M+24.6% | $33.24M+11.7% | $29.75M+48.1% | $20.08M-8.1% | $21.85M+1,409% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aurinia Pharmaceuticals's profit margins?
- Gross margin is 89.7% and operating margin is 41.7%, with a 100.0% net margin.
- Where does Aurinia Pharmaceuticals's income statement data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.